Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Combined With Rituximab and Lenalidomide (ZR2) Versus R2 Regimen in Newly Diagnosed Follicular Lymphoma
NCT07505849Phase 2Not yet recruiting
- Sponsor
- Keros Therapeutics
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Phase 2, randomised, open-label trial of zanubrutinib in follicular lymphoma (FL) (2 arms), sponsored by Keros Therapeutics. Primary endpoint: Complete Response rate at 24 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07505849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505849.